4.8 Review

Crohn's disease

期刊

LANCET
卷 389, 期 10080, 页码 1741-1755

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/S0140-6736(16)31711-1

关键词

-

资金

  1. Takeda Pharmaceuticals
  2. Merck
  3. Abbvie
  4. Janssen Janssen
  5. Genentech
  6. Mitsubishi
  7. Ferring
  8. Norgine
  9. Tillots
  10. Vifor
  11. Therakos
  12. Pharmacosmos
  13. Pilege
  14. Bristol Meyers Squibb
  15. UCB Pharmaceuticals
  16. Hospira
  17. Celltrion
  18. Takeda
  19. Biogaran
  20. Boehringer-Ingelheim
  21. Lilly
  22. Pfizer
  23. HAC-Pharma
  24. Index Pharmaceuticals
  25. Amgen
  26. Sandoz
  27. Forward Pharma GmbH
  28. Celgene
  29. Biogen
  30. Lycera
  31. Samsung Bioepis

向作者/读者索取更多资源

Crohn's disease is a chronic inflammatory disease of the gastrointestinal tract, with increasing incidence worldwide. Crohn's disease might result from a complex interplay between genetic susceptibility, environmental factors, and altered gut microbiota, leading to dysregulated innate and adaptive immune responses. The typical clinical scenario is a young patient presenting with abdominal pain, chronic diarrhoea, weight loss, and fatigue. Assessment of disease extent and of prognostic factors for complications is paramount to guide therapeutic decisions. Current strategies aim for deep and long-lasting remission, with the goal of preventing complications, such as surgery, and blocking disease progression. Central to these strategies is the introduction of early immunosuppression or combination therapy with biologicals in high-risk patients, combined with a tight and frequent control of inflammation, and adjustment of therapy on the basis of that assessment (treat to target strategy). The therapeutic armamentarium for Crohn's disease is expanding, and therefore the need to develop biomarkers that can predict response to therapies will become increasingly important for personalised medicine decisions in the near future. In this Seminar, we provide a physician-oriented overview of Crohn's disease in adults, ranging from epidemiology and cause to clinical diagnosis, natural history, patient stratification and clinical management, and ending with an overview of emerging therapies and future directions for research.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据